Navigation Links
Targeted Nanoparticles Offer Promise in the Battle Against Cancer
Date:10/16/2007

RESEARCH TRIANGLE PARK, N.C., Oct. 16 /PRNewswire/ -- Liquidia Technologies announces a series of speaking engagements by company founder and University of North Carolina-Chapel Hill professor, Joseph DeSimone. At a series of events this fall, Dr. DeSimone will discuss drug delivery applications of the PRINT(TM) platform and his ongoing research in cancer therapeutics.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060614/CLW002LOGO )

-- Prostate Cancer Foundation Scientific Retreat - October 12, Lake Tahoe,

NV

-- NCI Nanotechnology Alliance Investigators Meeting - October 16, Chapel

Hill, NC

-- Williamsburg BioProcessing Foundation Conference - November 1, Austin,

TX

-- Nanomedicine & Drug Delivery Symposium - November 2, Boston, MA

-- Nanotechnology in Biology and Medicine Conference - November 5,

Charlotte, NC

-- American Chemical Society Workshop - November 7, Lake Tahoe, NV

"These engagements are a clear indication of the widespread commercial and scientific interest in the PRINT(TM) technology platform, developed by Dr. DeSimone and his colleagues," says Dr. Bill Weiser, General Manager of Pharmaceuticals at Liquidia. "The PRINT platform enables Liquidia and its licensees to develop novel engineered drug therapies based on precise nanoparticle design and scalable manufacturing capabilities."

DeSimone and researchers at Liquidia and UNC are exploring applications for the PRINT platform in a number of areas including delivery of oligonucleotides and cancer therapeutics. In collaboration with the National Cancer Institute (NCI), DeSimone is examining the effect of particle size and shape on cellular uptake, and the ability of specific ligands on the surface of a nanocarrier to promote cellular targeting.

During the 2007 Controlled Release Society Meeting, DeSimone presented data from a melanoma mouse model, in which 200 nm PRINT particles with aVb3 ligands successfully targeted the angiogenic tumor vasculature. Based on further pre-clinical studies, a PRINT-based cancer therapeutic is expected to enter clinical trials in 2008.

About Liquidia

Liquidia Technologies Inc. is an innovative nanotechnology company that designs, develops, and manufactures precisely engineered particles and films for a wide variety of life and materials science applications. Liquidia's proprietary PRINT(TM) platform is unique in its ability to replicate and produce nanoscale features with absolute control over particle size, shape, and composition. The company was founded in 2004 on the discoveries of Professor Joseph DeSimone at the University of North Carolina, Chapel Hill and is located in Research Triangle Park, North Carolina. For additional information, please visit http://www.liquidia.com.


'/>"/>
SOURCE Liquidia Technologies
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
3. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
4. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
7. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
9. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
10. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed ... geared towards children of all ages; it is a non-competitive, non-timed event, which is ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
Breaking Medicine News(10 mins):